Cowen & Co. analyst Chris Shibutani maintained a Hold rating on Puma Biotechnology (PBYI) yesterday and set a price target of $27. The company’s shares closed yesterday at $14.46, close to its 52-week low of $14.24.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.4% and a 41.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Puma Biotechnology with a $22.43 average price target, representing a 55.1% upside. In a report issued on May 29, Goldman Sachs also maintained a Hold rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $65.45 and a one-year low of $14.24. Currently, Puma Biotechnology has an average volume of 1.07M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.
